New asthma inhaler passes first safety check in small study
NCT ID NCT06385964
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested an experimental drug called SHR-4597, given as an inhaled powder, in 62 healthy volunteers and people with asthma. The main goal was to see if it is safe and tolerable. The study gave single doses to healthy people and multiple doses over several days to asthma patients with mild to severe symptoms. This is a first step to see if the drug is safe enough for further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-4597 (an experimental drug taken by inhaling a dry powder)
What this could lead to
If safe, this could lead to a new inhaled treatment option for asthma that helps control symptoms.
What could go wrong
This is a very early Phase 1 trial focused only on safety, not on whether the drug works. It is small (62 people) and may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 200433, China